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Absence seizures (ASs) are the hallmark of childhood/juvenile absence epilepsy. Monotherapy with ﬁrst-
line anti-absence drugs only controls ASs in 50% of patients, indicating the need for novel therapeutic
targets. Since serotonin family-2 receptors (5-HT2Rs) are known to modulate neuronal activity in the
cortico-thalamo-cortical loop, the main network involved in AS generation, we investigated the effect of
selective 5-HT2AR and 5-HT2CR ligands on ASs in the Genetic Absence Epilepsy Rats from Strasbourg
(GAERS), a well established polygenic rat model of these non-convulsive seizures. GAERS rats were
implanted with fronto-parietal EEG electrodes under general anesthesia, and their ASs were later
recorded under freely moving conditions before and after intraperitoneal administration of various 5-
HT2AR and 5-HT2CR ligands. The 5-HT2A agonist TCB-2 dose-dependently decreased the total time
spent in ASs, an effect that was blocked by the selective 5-HT2A antagonist MDL11,939. Both MDL11,939
and another selective 5-HT2A antagonist (M100,907) increased the length of individual seizures when
injected alone. The 5-HT2C agonists lorcaserin and CP-809,101 dose-dependently suppressed ASs, an
effect blocked by the selective 5-HT2C antagonist SB 242984. In summary, 5-HT2ARs and 5-HT2CRs
negatively control the expression of experimental ASs, indicating that selective agonists at these 5-HT2R
subtypes might be potential novel anti-absence drugs.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).-HTR); Knockout, (KO); Meta-
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Since the original suggestion in the late 1950s' (Bonnycastle
et al., 1957), many studies have supported the idea that the sero-
tonin (5-HT) system might be implicated in both focal and gener-
alized epilepsy. In particular, it has been shown that an increase in
5-HT tone is associated with an increased seizure threshold (and/or
antiepileptic activity), whilst a reduced seizure threshold follows a
decrease in 5-HT levels (reviewed in (Bagdy et al., 2007)). More-
over, many anti-epileptic drugs enhance brain extracellular 5-HT
levels and many selective serotonin reuptake inhibitors (SSRIs)
show an antiepileptic effect (Bagdy et al., 2007). Despite this large
body of evidence, none of the currently available anti-epileptic
drugs preferentially targets the 5-HT system, probably because of
the lack of selective/speciﬁc ligands, the presence of harmful off-
target effects and the complexity of the 5-HT receptor (5-HTR)
system and its signaling pathways (Hannon and Hoyer, 2008;
Stroth and Svenningsson, 2012).e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and the generation of selective pharmacological and genetic tools,
i.e., knockout (KO) mice, to investigate the contribution of indi-
vidual receptors is fairly recent (Hannon and Hoyer, 2008). Among
the different 5-HTR subtypes (Hoyer et al., 2002), many lines of
evidence suggest an involvement of 5-HT2Rs in seizures (reviewed
in (Di Giovanni and De Deurwaerdere, 2016; Guiard and Di
Giovanni, 2015; Isaac, 2005; Jakus and Bagdy, 2011)). 5-HT2CR KO
mice display spontaneous tonic-clonic seizures which are occa-
sionally lethal (Tecott et al., 1995), and a decreased threshold for
various convulsing stimuli, e.g., kindling, pentylenetetrazol (PTZ),
electroshock, audiogenic stimuli (Applegate and Tecott, 1998;
Heisler et al., 1998). Further evidence of the protective role for 5-
HT2CRs against convulsive seizures comes from experiments us-
ing non-selective 5-HT2C agonists which raise the threshold for
PTZ- and electroshock-induced seizures (Upton et al., 1998). On the
other hand, some 5-HT2CR agonists with different pharmacological
proﬁles, i.e., meta-chlorophenylpiperazine (mCPP) and lorcaserin,
but not RO60-0175 (Martin et al., 1998) are able to stop the elon-
gation of the electrically triggered hippocampal maximal dentate
gyrus activation (MDA) in a limbic seizure model (Orban et al.,
2014). As for 5-HT2ARs, fewer studies have investigated the role
of these receptors in seizures, with most evidence showing that
their activation has an antiepileptic effect (Gharedaghi et al., 2014;
Guiard and Di Giovanni, 2015).
The evidence of a role for 5-HT2Rs in generalized non-
convulsive seizures is more limited and the interpretation of
these studies is hampered by the use of relatively unselective drugs
(Bagdy et al., 2007; Di Giovanni and De Deurwaerdere, 2016; Guiard
and Di Giovanni, 2015). In the groggy model of absence seizures
(ASs) (Tokuda et al., 2007), the 5-HT2A/2C mixed agonist DOI dose-
dependently reduces ASs, an effect that is blocked by the non-
selective 5-HT2R antagonist ritanserin (Ohno et al., 2010). In
contrast, in the AY-9944 model of atypical ASs, mCPP has no effect,
DOI dose-dependently decreases ASs and the moderately selective
5-HT2AR antagonist ketanserin increases ASs in a non-dose-
dependent manner (Bercovici et al., 2006). These authors
concluded that 5-HT2ARs were responsible for this effect, although
no 5-HT2AR antagonist was tested against the anti-absence action
of DOI. As far as typical ASs are concerned, experiments in the
Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats, one of the best char-
acterized rat models of these type of non-convulsive seizures
(Coenen and Van Luijtelaar, 2003), have found that mCPP decreases
ASs via 5-HT2CRs (Jakus et al., 2003). Moreover, SB-242084 a se-
lective 5-HT2CR antagonist, has no effect on ASs when administered
alone, suggesting that 5-HT2CRs do not play a tonic modulatory role
(Jakus and Bagdy, 2011; Jakus et al., 2003). In the other well char-
acterized rat model of typical ASs, the Genetic Absence Epilepsy Rat
from Strasbourg (GAERS) (Danober et al., 1998) the contribution of
the 5-HT system to ASs has only been partly investigated, probably
because of the early negative results obtained with broad-spectrum
ﬁrst-generation 5-HTR agonists and antagonists or following
modulation of the 5-HT tone by 5-HT uptake blockers and pre-
cursors (Marescaux et al., 1992a, 1992b) (reviewed in (Danober
et al., 1998)).
In the present study, we evaluated the effects of pharmacolog-
ical manipulation of 5-HT2Rs on typical ASs and the interictal EEG
in GAERS using drugs selective for 5-HT2ARs and 5-HT2CRs. The
potent 5-HT2AR agonist TCB-2 (McLean et al., 2006) was used in
combination with the selective 5-HT2AR antagonists MDL11,939
(Dudley et al., 1988) and M100,907 (Table 1) (Kehne et al., 1996). As
far as 5-HT2CRs were concerned, we used CP-809,101, which shows
~1000 fold selectivity for the 5-HT2CR over 5-HT2AR and represents
the most selective 5-HT2CR drug currently available (Siuciak et al.,
2007), and SB-242084, the most selective 5-HT2CR antagonistsynthetized to date (Di Matteo et al., 2000; Kennett et al., 1997)
(Table 1). Moreover, the anti-absence action of lorcaserin (Thomsen
et al., 2008) was also investigated because, although it has only an
approximately 10-fold higher afﬁnity for 5-HT2CRs compared to 5-
HT2ARs (Table 1), it is the ﬁrst-in-class 5-HT2CR agonist available for
human use (FDA, 2012) and has shown an antiepileptic proﬁle in an
animal model of temporal lobe epilepsy (Orban et al., 2014). Our
results show that both 5-HT2ARs and 5-HT2CRs negatively control
the expression of experimental ASs, suggesting that selective ago-
nists at these 5HT2R subtypes might be potential novel anti-
absence drugs.
2. Methods
Male GAERS rats (3e5 months old) were obtained from a colony
bred at Cardiff University. Animals were housed in a 12:12 light
cycle (lights on at 10.00 p.m. and off at 10.00 a.m.). All animal
procedures were approved by the UK Home Ofﬁce and carried out
in accordance with Cardiff University ethical guidelines and in
conformity with international law and policies (EU Directive, 2010/
63/EU for animal experiments, ARRIVE guidelines and the Basel
declaration including the 3R concept). All efforts were made to
minimize animal suffering and to reduce the number of animals
used (Lidster et al., 2015).
2.1. Surgery and EEG recordings
GAERS underwent chronic electrode implantation under gen-
eral anesthesia (2% isoﬂuorane). Epidural EEG electrodes (gold
plated screws, Svenska Dentorama AB, Sweden) were implanted
bilaterally over the frontal cortex, parietal cortex and in the cere-
bellum, as previously described (Cope et al., 2009). Animals were
allowed to recover for at least 5 days. At 10.00 a.m. on the day of the
experiment, the animals were placed into individual Plexiglas cages
with access to food and water, and connected to a pre-ampliﬁer
(0.08 Hz high-pass ﬁlter, impedance 10 MU) and in turn to an
analogue EEG ampliﬁer (4-channel BioAmp, SuperTech Inc.,
Hungary) (1000 gain, low-pass ﬁlter at 500 Hz). The signal was
digitized at 1000 Hz with a Cambridge Electronic Design (CED)
Micro3 D.130 digitizer using CED Spike2 v7.3.
2.2. Experimental protocol
Once GAERS had been connected to the recording apparatus,
they were left undisturbed for 1 h (habituation period). After that,
video and EEG recordings commenced and continued for 40 min
(control period). If the experiment involved pre-treatment of a 5-
HT2A/2C antagonist, the antagonist (or the corresponding vehicle)
was intraperitoneally (i.p.) injected 10 min before the end of the
control period. At the end of the control period, the animal was
injected (i.p.) with the 5-HT drug of interest (or corresponding
vehicle) and video and EEG recordings continued for the subse-
quent 2 h (treatment period). Drug injection order and doses were
randomized in an incomplete crossover design and each drug-naïve
animal received a maximum of three treatments in increasing dose
protocols (vehicle, low dose, high dose) or four treatments when
testing one dose of an agonist vs antagonist (e.g. vehicle þ vehicle,
vehicle þ agonist, antagonist þ vehicle, antagonist þ agonist). The
washout period was 5 days.
2.3. ASs detection and quantiﬁcation
The detection of spike-and-wave discharges (SWDs) was semi-
automatic, aided by the SeizureDetect script (kindly provided by
Steve Clifford, CED) in Spike2 v7.3 (CED, UK), designed to
Table 1
Selectivity proﬁle of 5-HT2A/2C drugs used in the studyi.
Compound 5-HT2A 5-HT2B 5-HT2c 2C/2A
Ki (nM) a pEC50b Efﬁcacy c Ki (nM) pEC50 Efﬁcacy Ki (nM) pEC50 Efﬁcacy
5-HT2ARs
TCB-2d 0.73 6.8 e e e e e e e e
MDL11,939e 2.8 e e 1419 e e 853 e e e
M100,907f 1.9e 8.9 e 261e 6 e 88e 7.7 e 0.06
5-HT2CRs
CP-809,101g 6 6.8 0.67 64 7.2 0.57 1.6 10 0.93 1585
Lorcaserinh 159 6.7 1 190 6.0 1 29 7.9 1 16
SB242084f 851 6.8 e 45 7.0 e 7.0 9 e 158
a Ki: binding afﬁnity.
b pEC50, potency: negative logarithm of the EC50 (half-maximal effective concentration).
c Efﬁcacy relative to response to a supramaximal 5-HT concentration.
d (McLean et al., 2006).
e (Pehek et al., 2006).
f (Bromidge et al., 1997).
g (Siuciak et al., 2007).
h (Thomsen et al., 2008).
i Modiﬁed from (Higgins et al., 2013a).
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pass-ﬁltered (DC remove, time constant 0.1 s) and the user selected
manually a interictal segment of control, awake desynchronized
EEG. The script automatically detected the crossings of a threshold
deﬁned as 5e9 SD above and below the mean voltage of the
manually selected interictal period. Subsequently the crossings
above threshold were grouped together in order to deﬁne putative
SWDs according to 4 parameters. In order to deﬁne the start of the
putative SWD, two crossings needed to be separated by less than
the max onset interval (0.2 s). To be incorporated into the putative
SWD the timing of the following crossings had to be lower than the
maximum continuation interval (0.4 s). Putative SWDs less than
0.5 s apart were amalgamated. Putative SWDs with a duration of
less than 1 s were discarded. The interval of consecutive crossings
in each putative SWD was then used to deﬁne instantaneous fre-
quencies (in the time domain). Only putative SWDs which had
75% of their peaks in the 5e12 Hz frequency range were selected,
resulting in the exclusion sleep/drowsiness epochs and artifacts.
This semi-automatic SWD selection was further reﬁned by visual
inspection with a custom made Matlab script (Matlab R2013b, The
Mathworks Inc., USA) and conﬁrmed by the concomitant presence
of behavioral arrest in the video recordings (Depaulis et al., 2016).
Three parameters of ASs were quantiﬁed: total time spent in ASs,
average duration of single ASs and total number of ASs (Marescaux
et al., 1992a). For each animal and dose, the quantiﬁcation of ASs
was done in 20 min epochs and the value of each of the three pa-
rameters during the treatment period was normalized by
expressing it as a percentage of the corresponding parameter in the
control period. All statistical tests were performed on the data
following this normalization (see section Statistical Analysis). For
clarity, data are presented in the ﬁgures as percentage of the cor-
responding vehicle group (100% dotted line in ﬁgures).2.4. Ictal EEG analysis
Spectral analysis of previously detected seizures was performed
in order to determine the peak frequency of SWDs and to investi-
gate possible changes induced by the drug treatment. Brieﬂy,
continuous wavelet transform (Morlet mother wavelet, f0 ¼ 1,
range 5e14 Hz) was employed to determine the time-frequency
proﬁle of SWDs using a Matlab script kindly provided by Dr Dmy-
tro Iatsenko (Iatsenko et al., 2013) (freely available at http://www.physics.lancs.ac.uk/research/nbmphysics/diats/tfr/). The instanta-
neous frequencies corresponding to each previously detected SWD
during the treatment period were extracted from the wavelet po-
wer maxima in the range 5e14 Hz. The mean frequency was
calculated for each SWD and then averaged across all SWDs for
each animal.2.5. Interictal EEG analysis
Spectral analysis of the interictal EEG was performed on the raw
data after preprocessing with Fieldtrip (Oostenveld et al., 2011).
This involved resampling the data to 200 Hz after applying an anti-
aliasing (low-pass) FIR ﬁlter. Each EEG recording was analyzed
blind and artifacts and sleep epochs were marked manually with
custom-made Matlab scripts. Time-frequency decomposition was
performed with a script kindly provided by Dmytro Iatsenko
(Leicester University, UK) performing short-time Fourier transform
(binning 1e80 Hz, Gaussian window, f0 ¼ 1) on 20-min bins,
matching those used for AS analysis. Samples corresponding to
previously detected artifacts, SWDs and sleep periods were
excluded from the analysis. Power spectra were then averaged over
time for each 20-min epoch. Five EEG bands were deﬁned for the
analysis: delta (1e4 Hz), theta (5e8 Hz), alpha (9e12 Hz), beta
(13e30 Hz) and gamma (31e80 Hz). Data within 48e52 Hz were
excluded from the analysis of the gamma band to avoid contami-
nation with the 50 Hz power line.2.6. Statistical analysis
All statistical analyses were performed with Graphpad Prism
version 5.00 (GraphPad Software, San Diego, USA). The effect of
drug administration on the expression of absence seizures was
analyzed via non-repeated measures two-way analysis of variance
(ANOVA) with drug and time as factors. Dunnet's post-hoc testing
was employed to test for the simple main effect of drug vs. vehicle
for the full treatment period, whereas Sidak's multiple comparison
test was applied to analyze the time-course of the drug effects for
each 20 min bin compared to the corresponding time for vehicle.
Statistical analysis on peak SWD frequency was performed using
unpaired t-test. The effect of drug administration on the interictal
EEG was analyzed via non-repeated measures two-way analysis of
variance (ANOVA) with the frequency bands and time as factors.
Fig. 1. Effects of the 5-HT2AR agonist TCB-2 and the 5-HT2AR antagonists MDL11,939 and M100,907 on ASs. (A) Representative EEG traces for GAERS injected i.p. with vehicle,
0.3 mg/kg TCB-2 and 0.3 mg/kg TCB-2 following pre-treatment with MDL11,939 (0.5 mg/kg, i.p.) (interruption in each trace indicates time of injection). Dose response curves for
TCB-2 effects on normalized total time spent in seizures (B), number of seizures (C) and seizure length (D). Pre-treatment with the selective 5-HT2AR antagonist MDL11,939 (0.5 mg/
kg) blocked the effect of TCB-2 (3 mg/kg) on the three seizure parameters. (E) Representative EEG traces for GAERS injected i.p. with vehicle, 0.5 mg/kg MDL11,939 and 0.5 mg/kg
M100,907 (interruption in each trace indicates time of injection). Effect of MDL11,939 (0.5 mg/kg) and M100,907 (0.5e3 mg/kg) on normalized total time spent in seizures (F),
seizure length (G) and number of seizures (H). Although no single time point reached signiﬁcance after post-hoc testing, both 5-HT2AR antagonists signiﬁcantly increased the time
spent in seizures and seizure length when considering the overall treatment time (see text for details). All values are normalized to the control period (40 to 0 min), and are
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course of the drug effect on the interictal EEG for each 20 min bin
compared to the corresponding time for vehicle. All quantitative
data are reported in the test and ﬁgures as mean ± SEM (unless
otherwise stated).
2.7. Drugs
The selective 5-HT2AR antagonist M100907 (Kehne et al., 1996)
was purchased from Sigma-Aldrich (UK). The selective 5-HT2CR
antagonist SB-242084 (Kennett et al., 1997), the potent 5-HT2AR
agonist TCB-2 (McLean et al., 2006), the selective 5-HT2AR antag-
onist MDL11,939 (Dudley et al., 1988) and the selective 5-HT2CR
agonist CP-809,101 (Siuciak et al., 2007) were purchased from
Tocris Biosciences (UK). The 5-HT2CR agonist Lorcaserin (Thomsen
et al., 2008) was a kind gift from Arena Pharmaceuticals Inc.
(USA). All common laboratory reagents were purchased from
Sigma-Aldrich (UK). TCB-2 and lorcaserin were dissolved in 0.9%
saline. CP-809,101 was dissolved in 2% Tween 80. SB-242084 and
M100907 were dissolved in 25 mM citric acid, 8% (2-
Hydroxypropyl)-b-cyclodextrin (w/v) in 0.9% saline. MDL11,939
was dissolved in 0.9% saline and 5% glacial acetic acid and the pH
adjusted to 7.0 with NaOH. Drugs were selected for being the most
selective 5-HT2AR/5-HT2CR agents available to date for research use
(Table 1) and, in the case of Lorcaserin, in view of its clinical use
(FDA, 2012). TCB-2 was selected for its high afﬁnity for 5-HT2AR
because, to the best of our knowledge, no selective 5-HT2AR agonist
has been synthesized to date.
3. Results
The behavioral and EEG features of ASs recorded in vehicle-
treated, freely moving GAERS were similar to those previously re-
ported for this experimental model under similar experimental
conditions (Cope et al., 2009; Danober et al., 1998). These included
behavioral arrest, with occasional head and vibrissae twitching,
and SWDs of 16.1 ± 14.3 s duration and 6.90 ± 0.72 Hz peak fre-
quency (n ¼ 8914 seizures, mean ± standard deviation) (see
Fig. 3A).
3.1. Effect of 5-HT2AR modulation on spontaneous ASs
GAERS were injected i.p. with vehicle (n¼ 9) or TCB-2 (0.03, 0.3,
3 mg/kg; n ¼ 6e9 for each dose) in a randomized order, and the
resulting effects (normalized to the effect of the vehicle group) are
shown in Fig. 1AeD. As revealed by post-hoc testing for the simple
main effect of the drug, TCB-2 decreased the total time spent in
seizure compared to vehicle (0.03 mg/kg: 10.1 ± 4.6% overall
decrease, p < 0.05; 0.3 mg/kg: 69.4 ± 9.2% overall decrease,
p < 0.001; 3 mg/kg: 97.4 ± 1.5% overall decrease, p < 0.001). This
effect was dose-dependent (0.03 vs 0.3 mg/kg: p < 0.001; 0.3 vs
3 mg/kg: p < 0.001) (Fig. 1B). The average number of seizures was
also signiﬁcantly decreased by all doses of TCB-2 (0.03 mg/kg:
14.4 ± 9.7% overall decrease, p < 0.001; 0.3 mg/kg: 68.6 ± 7.2%
overall decrease, p < 0.001; 3 mg/kg: 93.7 ± 2.8% overall decrease,
p < 0.001), an effect that was dose-dependent (0.03 vs 0.3 mg/kg:
p < 0.001; 0.3 vs 3 mg/kg: p < 0.001) (Fig. 1C). There was no effect
on the length of individual ASs at 0.03, while 0.3 mg/kg TCB-2
elicited a reduction in seizure length at 20 min post-injectionexpressed as a percentage of their respective vehicle group for clarity. Values represent mea
MDL11,939 was injected 10 min before TCB-2 administration. Asterisks indicate p < 0.05 fo
group (two-way ANOVA, Sidak's multiple comparison test). TCB-2 (0.03e3 mg/kg): n ¼ 9
n ¼ 11e9; MDL11,939 (0.5 mg/kg): n ¼ 11.(62.2 ± 4.9% decrease, p < 0.001). Moreover 3 mg/kg TCB-2 eli-
cited a drastic reduction of seizure length (81.1 ± 7.0% decrease at
80e120 min, p < 0.001) (Fig. 1D). Note that during the 40 and
60 min post-injection time-bins of 3 mg/kg TCB-2 no seizures were
observed, and thus no estimation of seizure length was possible
(gaps in Fig.1D). Finally, an increase of the SWDpeak frequencywas
observed only at the highest dose of TCB-2 (vehicle: 7.1 ± 0.1 Hz;
3 mg/kg TCB-2: 7.6 ± 0.2 Hz; p < 0.05) (Fig. 3B).
Pre-treatment with the 5-HT2A antagonist MDL11,939 (0.5 mg/
kg, i.p., n ¼ 7) blocked the effect of 0.3 mg/kg TCB-2 on the total
time spent in seizure (Fig.1A, B) and seizure length (Fig.1D) (simple
main effect of 0.5 mg/kg MDL11,939 þ 0.3 mg/kg TCB-2 vs vehicle,
ns), and greatly attenuated the effect of the agonist on the number
of seizures (Fig. 1C) (simple main effect of MDL11,939 þ TCB-2 vs
vehicle, 11.5 ± 7.9% overall decrease, p < 0.05; compared to
68.6 ± 7.2% overall decrease for 0.3 mg/kg TCB-2 vs vehicle).
Interestingly, MDL11,939 (0.5 mg/kg, n ¼ 11) on its own signiﬁ-
cantly increased the total time spent in ASs compared to vehicle
(overall 25.5 ± 21.1% increase, p < 0.05). Moreover, a signiﬁcant
effect of this drug was observed on seizure length (overall
23.5 ± 18.9% increase, p < 0.05), but not on seizure number. To
further conﬁrm these effects of MDL11,939, another selective 5-
HT2AR antagonist, M100,907, was injected in a naïve group of
GAERS (Fig.1EeH). Post-hoc testing on the simplemain effect of the
drug showed that M100,907 induced a signiﬁcant increase in the
total time spent in ASs both at 0.5 mg/kg (31.7 ± 20.4% overall in-
crease, p < 0.001, n ¼ 11) and at 3 mg/kg (20.1 ± 14.6% overall in-
crease, p < 0.05, n ¼ 9). This effect was driven by a signiﬁcant
increase in the seizure length, both at 0.5 mg/kg (52.3 ± 20.7%
overall increase, p < 0.001) and at 3 mg/kg (53.2 ± 20.3% overall
increase, p < 0.001). In addition, M100,907 induced a small, but
signiﬁcant, decrease in the number of ASs both at 0.5 mg/kg
(10.4 ± 10.7% overall decrease, p < 0.01) and at 3 mg/kg (17.9 ± 9.2%
overall decrease, p < 0.01). Moreover, while no signiﬁcant change of
the peak SWD frequency was found upon treatment with
MDL11,939, both doses of M100,907 induced a modest, but signif-
icant decrease in the SWD peak frequency (vehicle: 7.1 ± 0.1 Hz vs
0.5 mg/kg: 6.85 ± 0.05 Hz; p < 0.05; vs 3 mg/kg: 6.9 ± 0.05;
p < 0.05) (Fig. 3B).
The block of ASs by TCB-2 was accompanied by behavioral
components typical of 5-HT2AR activation in rodents (e.g., wet dog
shakes, head twitches) (Bedard and Pycock, 1977), that were short-
lasting compared to its antiabsence effect. Importantly, the effect of
TCB-2 on both ASs and the animal behavior was blocked by pre-
treatment with the 5-HT2A antagonist MDL11,939, conﬁrming that
the effect was indeed driven by the activation of 5-HT2ARs. In
summary, these results indicate that selective activation of 5-
HT2ARs markedly decreases spontaneous, genetically determined
ASs and that this 5-HTR subtype exerts a negative tonic modulation
of these non-convulsive seizures.3.2. Effect of 5-HT2CR modulation on spontaneous ASs
We next investigated the action of the selective 5-HT2CR agonist
CP-809,101 in different groups of GAERS at doses (0.3, 3 and 10 mg/
kg, n ¼ 6e10 per dose) similar to those used in previous studies
(Higgins et al., 2013b; Siuciak et al., 2007). No effect of 0.3 mg/kg
was found on the total time spent in ASs, seizure length and
number of seizures (Fig. 2AeD). However CP-809,101 induced an ± SEM. Time zero indicates the time of injection of the agonist, while the antagonist
r a given time bin in the treatment group vs the corresponding time bin in the vehicle
e6; TCB-2 (0.3 mg/kg) ± MDL11,939 (0.5 mg/kg): n ¼ 7; M100,907 (0.5e3 mg/kg):
Fig. 2. The 5-HT2CR agonists lorcaserin and CP-809,101 dose-dependently decrease ASs. (A) Representative EEG traces for GAERS injected i.p. with vehicle, 3 mg/kg CP-809,101 and
3 mg/kg CP-809,101 following pre-treatment with SB242084 (0.5 mg/kg, i.p.) (interruption in each trace indicates time of injection). Dose response curve of CP-809,101 at 0.3-3-
10 mg/kg for normalized total time spent in seizure (B), number of seizures (C) and seizure length (D). Pre-treatment with the selective 5-HT2CR antagonist SB2402084 (0.5 mg/kg)
partially blocked the effect of CP-809,101 (3 mg/kg) on the three seizures parameters. (E) Representative EEG traces for GAERS injected i.p. with vehicle, 3 mg/kg lorcaserin and
3 mg/kg lorcaserin following pre-treatment with SB242084 (0.5 mg/kg, i.p.) (interruption in each trace indicates time of injection). Dose response curves of lorcaserin (right side of
the ﬁgure) at 0.3-3-10 mg/kg for normalized total time spent in seizure (F), number of seizures (G) and seizure length (H). Pre-treatment with the selective 5-HT2CR antagonist
SB2402084 (0.5 mg/kg) partially blocked the effect of CP-809,101 (3 mg/kg) on the three seizures parameters. All values are normalized to the control period (40 to 0 min), and are
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overall reduction, p < 0.001) and 10 mg/kg (78.9 ± 8.3% overall
reduction, p < 0.001). The effect of 3 mg/kg was strong but of short
duration, with post-hoc testing showing a signiﬁcant effect for the
ﬁrst 40 min post-injection (64.7 ± 11.7% decrease, p < 0.05),
whereas for 10 mg/kg the total time spent in ASs was drastically
reduced throughout the 2 h treatment period (Fig. 2B). Moreover,
whereas 3 mg/kg CP-809,101 increased seizures length
(21.4 ± 14.4% overall increase, p < 0.05), 10 mg/kg elicited a sig-
niﬁcant reduction in seizure length (39.5 ± 9.5% overall reduction,
p < 0.001) (Fig. 2D). The number of seizures was reduced for both 3
and 10 mg/kg CP-809,101, an effect that was signiﬁcant for 60 min
(58.7 ± 9.5% mean reduction, p < 0.05) and 100 min post-injection
(72.7 ± 8.6%mean reduction, p < 0.05) (Fig. 2C). Pre-treatment with
0.5 mg/kg SB-242084 (n ¼ 10) blocked the effect of CP-809,101
(3 mg/kg) on the total time spent in ASs (simple main effect of
0.5mg/kg SB-242084þ 3mg/kg CP-809,101 vs vehicle, ns), but only
partially blocked the effect of this agonist on seizure length and
number of seizures (Fig. 2AeD). Moreover, a signiﬁcant increase of
the SWD peak frequency was observed following the highest dose
of CP-809,101 (vehicle: 7.1 ± 0.1 Hz,10mg/kg: 7.5 ± 0.1 Hz; p < 0.05)
(Fig. 3B).
The action of the less selective 5-HT2C agonist lorcaserin
(Thomsen et al., 2008) (0.3, 3, 10 mg/kg; n ¼ 6e10 per dose) was
more complex than that observed following CP-809,101 treatment.
At 0.3 mg/kg lorcaserin had no signiﬁcant effect on total time spent
in ASs, seizure length and number of seizures (Fig. 2F, G, H).
Although the overall effect of 3 mg/kg lorcaserin was only a small
but signiﬁcant decrease in the total time spent in ASs (10.1 ± 15.2%,
p < 0.05), post-hoc testing showed that this action was due to clear
time-dependent biphasic effect, i.e. a marked decrease in total AS
time during the ﬁrst 40 min post-injection (20 min: 78.9 ± 5.7%
p < 0.001; 40 min; 62.6 ± 14.9%, p < 0.01), which was followed by
an increase 100 min post-injection (69.8 ± 21.5; p < 0.01) (Fig. 2F).
This complex action of 3 mg/kg lorcaserin on total AS time could be
explained by the different effect that this dose had on the number
of seizures and seizure length, with the former markedly
decreasing for almost all time points post-injection (overall
reduction: 53.6 ± 6.5%, p < 0.001) (Fig. 2G) while the latter was
increased during the same observation period (overall enhance-
ment: 201 ± 30%, p < 0.001) (Fig. 2H). The higher dose of lorcaserin
(10 mg/kg) elicited an overall more potent reduction in the total
time spent in ASs (overall decrease: 54.5 ± 7.5%, p < 0.001) which
could also be explained by a marked reduction in the number of
seizures. A trend for an increase in seizure lengthwas evident in the
second hour of the recording although no individual time bin
reached signiﬁcance in the post-hoc testing (Fig. 2H). Moreover, we
observed no change in the SWD peak frequency following any
doses of locarserin (Fig. 3B).
Pre-treatment with the selective 5-HT2C antagonist SB 242084
(Di Matteo et al., 2000) (0.5mg/kg, n¼ 9) almost fully abolished the
effect of lorcaserin (3 mg/kg) on the total time spent in ASs (simple
main effect of SB 242084 þ lorcaserin vs vehicle, ns), but only
partially blocked the effect of the agonist on seizure length and
number of seizures (Fig. 2FeH). SB 242084 injected alone (n ¼ 10)
had no signiﬁcant effects on the total time spent in seizures and on
seizure length. Surprisingly, SB 242084 decreased the number of
seizures in the ﬁrst 20 and 40 min post-injection (20 min:
30.1 ± 8.7% p < 0.01; 40 min; 30.1 ± 6.4%, p < 0.05) (Fig. 2FeH). Noexpressed as a percentage of their respective vehicle group for clarity. Values represent mea
SB2402084 was injected 10 min before the agonist administration. Asterisks indicates p <
vehicle group (two-way ANOVA, Sidak's multiple comparison test). CP-809,101 (0.3e10 m
(0.3e10 mg/kg): n ¼ 8e6; lorcaserin (3 mg/kg) ± SB242084 (0.5 mg/kg): n ¼ 9.change in the SWD peak frequency was observed following treat-
ment with SB 242084 (Fig. 3B).
Both CP-809,101 and locarserin produced 5-HT2C behavioral
effects consistent with those reported previously (Di Giovanni and
De Deurwaerdere, 2016). In particular penile grooming was
observed at all doses of both 5-HT2C agonists, and hypolocomotion
was evident especially at high doses (i.e., 10 mg/kg lorcaserin and
CP-809,101). These effects were short-lasting compared to their
antiabsence effect and antagonized by pre-treatment with the se-
lective 5-HT2C antagonist SB 242084, which had no behavioral ef-
fect on his own, consistent with previous reports (Higgins et al.,
2001; Kennett et al., 1997). In summary, these results indicate
that selective activation of 5-HT2CRs decreases spontaneous,
genetically determined ASs and that this 5-HTR subtype does not
appear to exert a tonic modulation on these non-convulsive sei-
zures. Of note, SB 242084 showed an antiabsence effect at some
time-points, conﬁrming the complexity of the 5-HT2CR system (see
(Di Giovanni and De Deurwaerdere, 2016)).
3.3. Effects of 5-HT2AR and 5-HT2CR agonists on interictal EEG
In addition to modifying ASs, both at the EEG and behavioral
level, the highest doses of TCB-2 (3 mg/kg) and CP-809,101 (10 mg/
kg) were also able to produce signiﬁcant modiﬁcations of the po-
wer of different frequency bands in the interictal EEG (Fig. 4). TCB-2
induced a long-lasting decrease in the power of the gamma
(26.4± 4.4% mean reduction, p < 0.001) and alpha (28.0 ± 8.5%
mean reduction, p < 0.001 vs vehicle) frequency bands. CP-809,101
elicited a reduction in the gamma band power (26.1 ± 21.5%, mean
decrease, p < 0.05) and a drastic increase in the delta band
(64.5 ± 23.0% mean increase, p < 0.001). Finally, a trend for an in-
crease in the delta band power and a decrease in the alpha band
was apparent in the interictal EEG following the injection of 10 mg/
kg lorcaserin although no individual time epoch reached statistical
signiﬁcance.
4. Discussion
The main conclusions of this study are twofold i) selective
activation of both 5-HT2ARs and 5-HT2CRs decreases spontaneous,
genetically determined ASs, and ii) only 5-HT2ARs exert a negative
tonic modulation on these non-convulsive seizures.
4.1. Effect of 5-HT2AR ligands on ASs
5-HT2ARs have not previously been implicated in the patho-
genesis or modulation of ASs, except from the indirect evidence
provided by the block of ASs by DOI, a mixed 5-HT2A/2C agonist, in
the groggy rats, a model of these non-convulsive seizures that still
remains to be fully characterized (Ohno et al., 2010). Regardless of
the current lack of highly selective 5-HT2A agonists (Nichols, 2004;
Roth, 2011), the solidity of our results is supported by our approach
of using, as in previous studies by other groups (Fox et al., 2010;
Goda et al., 2013), a potent (i.e., nM afﬁnity) 5-HT2AR agonist
(TCB-2) in conjunction with a selective 5-HT2A antagonists
(MDL11,939) at a concentration that is known to block 5-HT2A- but
not 5-HT2C-mediated behaviors (Fletcher et al., 2002).
The presence of an inhibitory tone of 5-HT2ARs on ASs, as indi-
cated by a signiﬁcant increase in seizure length followingn ± SEM. Time zero indicates the time of injection of the agonist, while the antagonist
0.05 for a given time bin in the treatment group vs the corresponding time bin in the
g/kg): n ¼ 10e6; CP-809,101(3 mg/kg) ± SB242084 (0.5 mg/kg): n ¼ 10; lorcaserin
Fig. 3. Effect 5-HT2A/CRs modulation on SWDs peak frequency. (A) Representative spike and wave discharge (SWD) (red, top) and corresponding wavelet power spectrum on a
time-frequency representation (bottom). The peak frequency of the SWD was identiﬁed by extracting the instantaneous frequency of the power maximum in the range 5e14 Hz at
each time point of the SWD (magenta line in time-frequency plot) and subsequently calculating its mean. (B) Changes (mean ± SEM) in SWD peak frequency induced by
administration of 5-HT2AR and 5-HT2CR agonists and antagonists (bottom row) isolated or in combination with another drug (doses in mg/kg are reported at the bottom of the
graph). Asterisks indicate p < 0.05 (independent samples t-test for drug vs vehicle).
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study (MDL11,939 and M100,907), supports the idea that these
receptors tonically affect the duration of seizures in GAERS. The
conclusion that drugs blocking 5-HT2ARs might increase AS dura-
tion is in linewith the ﬁndings inWAG/Rij rats treated with atypical
antipsychotics where risperidone but not quetiapine was found to
increase AS duration (Citraro et al., 2015). Indeed, risperidone has a
~100 fold higher afﬁnity that quetiapine for 5-HT2ARs (Richtand
et al., 2007). However, it should be noted that atypical antipsy-
chotics affect multiple neurotransmitter systems which may also
underlie their effects on seizures.
4.2. Effects of 5-HT2CR ligands on ASs
Of the two 5-HT2CR agonists employed in this study, CP-809,101
displays a high (>1000 fold) selectivity for 5-HT2CRs over 5-HT2ARs
whereas lorcaserin has a lower (~10 fold) selectivity, though itspharmacokinetics and pharmacodynamics have been thoroughly
characterized. The selected doses of both substances are compa-
rable to those that elicit typical 5-HT2C-mediated behaviors in rats,
such as hypophagia and nicotine self-administration (Higgins et al.,
2013b; Thomsen et al., 2008). These two 5-HT2CR agonists induced
a dose-dependent, marked and SB 242084-sensitive decrease of
ASs up to 80 min post-injection. These results are consistent with,
and extend, those obtained in WAG/Rij rats with the non-selective
5-HT2/1BR agonist mCPP (Jakus et al., 2003). The lack of pro-
convulsant effect of the selective 5-HT2C antagonist SB 242084 on
ASs in GAERS, and in WAG/Rij rats (Jakus et al., 2003), might be
surprising since 5-HT2CR KO mice show convulsive seizures and a
higher susceptibility to different convulsive agents (Tecott et al.,
1995). However, it is well know that the pathophysiological
mechanisms leading to the expression of ASs are drastically
different from those of convulsive seizures (Crunelli and Leresche,
2002). Conversely, in our hands SB 242084 had at some time-
Fig. 4. Effect of TCB-2, CP-809,101 and lorcaserin on interictal EEG. (A1) TCB-2 (3 mg/kg, n ¼ 6) signiﬁcantly reduced EEG power in the alpha (8e12 Hz) and gamma (30e80 Hz)
bands compared to vehicle (n ¼ 7). (A2) Mean normalized power change at 40 min compared to the relative time point in the vehicle injected animals (top) and raw EEG spectrum
at 40 min compared to pre-drug (bottom). (B1) CP-809,101 (10 mg/kg, n ¼ 6) signiﬁcantly increased EEG power in the delta (1e4 Hz) and decreased power in the gamma band
(30e80 Hz) compared to vehicle (n ¼ 8). (B2) Mean normalized power change at 60 min compared to equivalent time point in the vehicle injected animals (top) and raw EEG
spectrum at 60 min compared to pre-drug (bottom). (C1) In the lorcaserin treated animals (10 mg/kg) no individual point reached statistical signiﬁcance after post-hoc testing,
although a trend for an effect in the delta and gamma bands is visible at 40 min (C2). All values are normalized to the control period (40 to 0 min), and are expressed as a
percentage of their respective vehicle group. Values represent mean ± SEM. Asterisks indicate p < 0.05 for a given time bin in the treatment group vs the corresponding time bin in
the vehicle group (two-way ANOVA, Sidak's multiple comparison test).
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spent in seizures). This convergence of anti-absence effects by 5-
HT2CR agonists and antagonists, although surprising, has already
been reported for their antidepressant effects (Di Giovanni and De
Deurwaerdere, 2016; Millan, 2005).
The marked reduction in ASs elicited by intermediate doses of
CP-809,101 and locarserin did not last for the entire 2 h observation
period. This may be due to pharmacokinetics/pharmacodynamics
features of the drugs, although the half-life of lorcaserin (>3 h)
(Higgins et al., 2013b) makes this possibility unlikely (no data is
available on CP-809,101 pharmacokinetics). Alternatively, the well-
known, rapid (within minutes) 5-HT2CR desensitization, which
however has been observed only in vitro however (Stout et al.,
2002), might explain the relatively short duration of the anti-
absence effect. Moreover, lorcaserin, but not CP-809,101, induced
a drastic increase in seizure length. It is difﬁcult at present to un-
derstand whether this contrasting effect may depend on the 5-
HT2C/2A selectivity of the two drugs, off-target effects and/or dif-
ferences in their functional selectivity (Urban et al., 2007; Stroth
and Svenningsson, 2012; Canal et al., 2013). Interestingly, the 5-
HT2CR agonist RO60-0175 (3 mg/kg, i.p.) produces a similar anti-
absence effect to that induced by CP-809,101, i.e., block of ASs
without an increase in seizure length (unpublished observation).
4.3. Pathophysiological signiﬁcance of 5-HT2AR- and 5-HT2CR-
elicited block of ASs
5-HT ﬁbers, originating from both dorsal and medial raphe
nuclei provide a diffuse distribution in the cortico-thalamo-cortical
circuit (Descarries et al., 2010), the key neuronal network respon-
sible for AS generation (Crunelli and Leresche, 2002), with a pref-
erential innervations of GABAergic cells in both brain regions
(Hornung, 2010). In particular, 5-HT2AR levels are relatively high in
the GABAergic neurons of the nucleus reticularis thalami (NRT) in
rats (Bonnin et al., 2006; Rodriguez et al., 2011), particularly on
their ﬁne and medium-size dendrites (Aznar et al., 2003; Li et al.,
2004; Rodriguez et al., 2011), but are also present to a lower level
in sensory thalamic nuclei (Li et al., 2004), though apparently ab-
sent in mice dorsal lateral geniculate nucleus (dLGN) (Coulon et al.,
2010). Moreover, 5-HT2AR and 5-HT2CR mRNA is detected in
GABAergic interneurons isolated from the dLGN of young rats
(Munsch et al., 2003). 5-HT2ARs and 5-HT2CRs are present in
cortical GABAergic interneurons, and to a lesser extent in pyramidal
neurons both in rats (Nocjar et al., 2015; Santana et al., 2004) and in
primates (De Almeida and Mengod, 2007).
In viewof this complex distribution of 5-HT2ARs and 5-HT2CRs in
the cortico-thalamo-cortical system, and because of the lack of data
on the cellular action of selective 5-HT2AR and 5-HT2CR agonists
and antagonists on the neuronal components of this network, it is
difﬁcult to precisely relate the present ﬁndings on the modulation
of ASs induced by systemic injection of 5-HT2ARs and 5-HT2CRs to
known physiological effects of these ligands on different thalamic
and cortical neuronal populations. Nevertheless, one might spec-
ulate that the putative 5-HT2AR-dependent i) decrease in ﬁring of
pyramidal cells in vivo (Ashby et al., 1990), ii) increase in IPSCs
in vitro in pyramidal cells (Zhou and Hablitz, 1999) and iii) depo-
larization of fast-spiking interneurons in vitro (Weber and Andrade,
2010) may all be contributing to a reduced ﬁring activity in the
putative cortical “initiation site” fromwhere SWDs ﬁrstly originate
(Polack et al., 2007), thus explaining the reduction of ASs observed
in the present study following 5-HT2AR activation. However, it
should be noted that the putative 5-HT2AR-dependent increase in
ﬁring rate (Zhang and Arsenault, 2005) and burst discharges which
have been reported in layer 5 pyramidal neurons in vivo (Celada
et al., 2008; Spindle and Thomas, 2014) could be favoring, andnot reducing, AS expression. At the thalamic level, 5-HT and puta-
tive 5-HT2CR agonists depolarize TC neurons (Chapin and Andrade,
2001;Meuth et al., 2006; Pape andMcCormick,1989). However, the
a-methyl-5-HT-elicited excitation of TC neurons (Coulon et al.,
2010) could be mediated by this drug activating 5-HT7Rs which
are known to control the excitability of this brain region (Chapin
and Andrade, 2001), and some TC neurons in higher order
thalamic nuclei are hyperpolarized by 5-HT (Monckton and
McCormick, 2002; Varela and Sherman, 2009). The depolarizing
action on TC neurons, together with the putative 5-HT2A/2CR-
mediated inhibition of NRT neuron burst ﬁring (McCormick and
Pape, 1990; McCormick and Wang, 1991), might counteract the
increased tonic GABAA inhibition of TC neurons in different absence
models (Cope et al., 2009), thus contributing to the reduction in ASs
by 5-HT2AR and 5-HT2CR agonists reported in the present study.
The possibility cannot be discarded, however, that the reduction
in ASs observed in the present study following systemic injection of
5-HT2AR and 5-HT2CR agonists might result from an indirect action
on other brain areas and/or physiological control systems. Firstly,
since both 5-HT2R subtypes are well expressed in the basal ganglia
(Li et al., 2004), which indirectly modulate AS generation
(Deransart and Depaulis, 2002), the 5-HT2AR- and 5-HT2CR-induced
reduction in ASs reported in the present study could be a conse-
quence of changes in ﬁring rate in these brain regions. Secondly,
since ASs are less common during activewakefulness and non-REM
sleep (Crunelli and Leresche, 2002; Depaulis and van Luijtelaar,
2006; Dewolfe et al., 2013), the 5-HT2AR- and 5-HT2CR-elicited
decrease in ASs might be due to changes in wake/sleep states eli-
cited by activation of these 5-HT receptor subtypes. Our study
design did not allow us to robustly record circadian sleep which
would have required acquiring a stable sleep baseline in GAERS
before drug injection and a different habituation protocol. However
we note that the available data on vigilance state alterations elicited
by 5-HT2AR and 5-HT2CR activation are contradictory. 5-HT2AR and
5-HT2CR KO mice show increased waking and reduced non-REM
sleep (Spindle and Thomas, 2014). On the other hand, systemic
administration of DOI (Monti and Jantos, 2006) and RO60-0175
(Martin et al., 1998; Monti and Jantos, 2015) increases waking
and reduces non-(rapid eye movement) REM and REM sleep.
Opposite results have been obtained with selective 5-HT2AR
agonist, and 5-HT2CR antagonists or non-selective 5-HT2A/2CR an-
tagonists that increased drowsiness and non-REM sleep and
reduced REM sleep (Morairty et al., 2008; Popa et al., 2005).
Nevertheless, our analysis of the interictal EEG in the same GAERS
rats where ASs were investigated indicate a decrease in gamma
waves by TCB-2 and CP-809,101, a decrease in alphawaves by TCB-2
and locarserin, and an increase of delta waves by CP-809,101 and
locarserin. Overall, therefore, these results provide indirect evi-
dence that these drugs decrease vigilance and increase non-REM
sleep, effects which might contribute to a reduction in ASs.
Indeed, it is interesting to note that 5-HT2AR and 5-HT2CR activation
produces similar actions on vigilance states and ASs whereas these
two classes of 5-HTRs produce opposite effects on a plethora of
other behaviors (Boulougouris and Robbins, 2010; Cunningham
et al., 2013; Di Giovanni and De Deurwaerdere, 2016; Di Giovanni
et al., 1999; Di Giovanni et al., 2008; Di Matteo et al., 2008;
Fletcher et al., 2012; Halberstadt et al., 2009; Winstanley et al.,
2004).
Another possibility that could be considered is that the stereo-
typic behaviors induced by 5-HT2AR and 5-HT2CR activation might
contribute to the reduction in absence seizures observed in this
study. Although a causal relationship between wet dog shakes,
head twitches and penile grooming cannot be fully ruled out, these
behaviours decrease and mostly disappear (our observation and
(Halberstadt and Geyer, 2013)) 30 min after the 5-HT2A/2CR agonist
M. Venzi et al. / Neuropharmacology 108 (2016) 292e304302administration while their antiabsence effect is of much longer
duration (>1.5 h).
Finally, it is worth to note that the highest doses of the 5-HT2AR
agonist TCB-2 and the 5-HT2CR agonist CP809101 produced a small
increase in the peak SWD frequency, while both doses of the 5-
HT2AR antagonist M100907 induced a small, but signiﬁcant
decrease in the peak SWD frequency. Although themechanism that
pace the rhythm of SWDs in not completely understood, it is known
that the peak SWD frequency differs in various experimental
models. In fact, gamma-hydroxybutyrate (GHB)- and PTZ-induced
SWDs are generally in the range of 4e6 Hz in the rat (McLean
et al., 2004; Venzi et al., 2015), while SWDs in genetic absence
models, as GAERS,WAG/Rij and Long Evans rats, generally appear at
frequencies of 7 Hz or higher (Coenen and Van Luijtelaar, 2003;
Crunelli and Leresche, 2002; Shaw, 2004). Therefore, it is reason-
able to assume that the rodent thalamortical network has the
intrinsic ability of producing SWD oscillations at various fre-
quencies and pharmacological interventions are capable of modu-
lating the pace of this oscillation. Although there are few examples
of this phenomenon, it was reported that systemic administration
of carbamazepine reduced the frequency of PTZ-elicited SWDs by
~0.5 Hz (McLean et al., 2004). Moreover, application of lidocaine on
the perioral region of the somatosensory cortex was shown to shift
the peak frequency of SWDs towards slower frequencies, although
this effect was less pronounced when recorded in brain regions
further away from the injection site (Sitnikova and van Luijtelaar,
2004). Clearly, the current lack of knowledge of the electrophysi-
ological effects of 5-HT2AR and 5-HT2CR agonists and antagonist in
cortical and thalamic neurons limits our ability to pinpoint a
mechanism on the action of these compounds on SWD frequency.
Future studies where local administration of drugs is coupled to
single units extracellular recordings in vivo at the site of adminis-
tration (Taylor et al., 2014) may help to elucidate this question.
4.4. Therapeutic potential of 5-HT2AR and 5-HT2CR ligands in ASs
The results reported here suggest that 5-HT2ARs and 5-HT2CRs
might be potential targets for novel anti-absence drugs. However,
the potential hallucinogenic activity of 5-HT2AR agonists must be
taken into account, though 5-hydroxytryptophan, 5-HT1AR antag-
onists, benzodiazepines and cannabinoid (CB) antagonists/inverse
agonists elicit head-twitch behavior, but lacks hallucinogenic ef-
fects in humans (Fantegrossi et al., 2005). Moreover, the activation
of 5-HT2AR heteroreceptor complexes with mGluR2 (Gonzalez-
Maeso et al., 2008) and D2Rs (Fuxe et al., 2014), CB1Rs (Vinals
et al., 2015) and 5-HT2CRs (Herrick-Davis et al., 2005) might be
important for the effects observed here and for potential targets for
drug development. Of note, our results with 5-HT2AR antagonists
warn that atypical antipsychotics, which exert their therapeutic
action, at least in part, by blocking 5-HT2AR-mediated responses
(Meltzer, 1995) and some 5-HT2AR antagonists, which are being
developed for the treatment of insomnia or anxiety, could poten-
tially induce an increase in seizure length in patients with ASs. 5-
HT2CR-targeting drugs, therefore, appear at present a safer and
more promising avenue for novel anti-absence medicines, espe-
cially in view of the fact that lorcaserin has already been approved
for human use. Moreover, since depression/anxiety-like symptoms
are common comorbid psychiatric disorders both in pediatric
epileptic patients (Vega et al., 2011) and animal models of absence
epilepsy (Jones et al., 2008; Sarkisova and van Luijtelaar, 2012), the
5-HT2CR agonist antidepressant properties (Di Giovanni and De
Deurwaerdere, 2016; Millan, 2005) make this receptor even a
more attractable target for treatment of absence epilepsy. Never-
theless, the ability of some 5-HT2CR agonists to increase seizure
length as shown in this study suggests caution.Conﬂict of interest
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